Editorial: Zebrafish Models for Human Disease Studies
Abstract
Zebrafish are an attractive vertebrate model organism for biomedical discovery (Tavares and Santos Lopes, 2013). The advantages of using zebrafish are well known and include cost-effectiveness, high fecundity, short generation time, external development, transparency of embryonic stages, and ease of genome manipulation. These features have provided investigators with a vertebrate model with unprecedented potential for the live imaging of biological processes (Okuda and Hogan, 2020) and genetic and drug screenings (Shah et al., 2015; Lam and Peterson, 2019). Zebrafish models have been used in developmental biology and embryogenesis (Briggs, 2002; Mathavan et al., 2005). They have been increasingly used to investigate human diseases in the last 2 decades due to the high degree of genetic, anatomical, and physiological similarities to humans (Dooley and Zon, 2000; Adamson et al., 2018). Over 80% of disease-causing human proteins have an orthologue in zebrafish, and the publishing of the zebrafish reference genome in 2013 accelerated disease modelling in this organism. Consequently, our understanding of disease mechanisms and the development of new medical treatments have expanded. Notably, new therapeutic targets and molecules have been identified using zebrafish, which are now being considered for human trials or are awaiting clinical applications. Nevertheless, more zebrafish models are needed to broaden our understanding of human diseases. The current research topic in…
How strong is the evidence?
Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Learning from First-Generation Qualitative Approaches in the IS Discipline: An Evolutionary View and Some Implications for Authors and Evaluators (PART 1/2)
- Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
- Prosthesis: New Technological Opportunities and Innovative Biomedical Devices
- The history and future of neural modeling for cochlear implants
- Ryanodine receptors: waking up from refractoriness
- Novel Transgenic Rabbit Model Sheds Light on the Puzzling Role of Matrix Metalloproteinase-12 in Atherosclerosis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.